Publication: 17

Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
      Google Scholar   
Citation:
Ann Oncol vol 18 (2) 331-7
Year:
2007
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
CA02599, CA03927, CA08025, CA21060, CA31946, CA32291, CA33601, CA35091, CA41287, CA45808, CA47555, CA47559, CA47577, CA47642, CA77298, CA77406, CA77658  
Corr. Author:
 
Authors:
               
Networks:
 
Study
CALGB-39902
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Carcinoma, Small Cell, Deoxycytidine, Female, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Salvage Therapy, Survival Rate